Efficacy of gemcitabine as second-line therapy after S-1 therapy failure in advanced pancreatic carcinoma

被引：2
|
作者：
Fukahori, Masaru [1 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.248
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
248
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study
    Viaud, Juliette
    Brac, Clemence
    Artru, Pascal
    Le Pabic, Estelle
    Leconte, Berengere
    Bodere, Anais
    Pracht, Marc
    Le Sourd, Samuel
    Edeline, Julien
    Lievre, Astrid
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 692 - 696
  • [22] Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
    Sano, Takeshi
    Aizawa, Rihito
    Ito, Katsuhiro
    Nakamura, Kiyonao
    Ogata, Takashi
    Takeda, Masashi
    Hamada, Akihiro
    Matsuoka, Takashi
    Kono, Jin
    Kita, Yuki
    Masui, Kimihiko
    Goto, Takayuki
    Sawada, Atsuro
    Akamatsu, Shusuke
    Ogawa, Osamu
    Mizowaki, Takashi
    Kobayashi, Takashi
    ANTICANCER RESEARCH, 2023, 43 (05) : 2119 - 2126
  • [23] A Phase II Study of S-1 Monotherapy as a First-line Combination Therapy of S-1 Plus Cisplatin as a Second-line Therapy, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: A Second Report
    Rino, Yasushi
    Yukawa, Norio
    Murakami, Hitoshi
    Wada, Nobuyuki
    Yamada, Roppei
    Hayashi, Tsutomu
    Sato, Tsutomu
    Ohshima, Takashi
    Masuda, Munetaka
    Imada, Toshio
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2010, 4 : 1 - 10
  • [24] EFFICACY OF LEVOFLOXACIN-BASED TRIPLE THERAPY AS A SECOND-LINE THERAPY AFTER TRIPLE THERAPY FAILURE
    Mahachai, V.
    Thongbai, T.
    Vilaichone, R.
    HELICOBACTER, 2012, 17 : 101 - 101
  • [25] Efficacy of levofloxacin-based triple therapy as a second-line therapy after triple therapy failure
    Mahachai, Varocha
    Chaithongrat, Supakarn Chaithongrat
    Vilaichone, Ratha-Korn
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 103 - 103
  • [26] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer : Is There a Standard?
    Almhanna, Khaldoun
    Kim, Richard
    ONCOLOGY-NEW YORK, 2008, 22 (10): : 1176 - 1183
  • [27] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1015 - 1026
  • [28] Pembrolizumab as second-line therapy for advanced urothelial carcinoma
    Douchet, G.
    ONCOLOGIE, 2017, 19 (5-6) : 205 - 206
  • [29] Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer
    Yamauchi, Junichi
    Kanai, Masashi
    Matsumoto, Shigemi
    Nishimura, Takafumi
    Yazumi, Shujiro
    Kami, Kazuhiro
    Kawaguchi, Yoshiya
    Yasuda, Hiroyasu
    Kitano, Toshiyuki
    Misawa, Akiko
    Ishiguro, Hiroshi
    Yoshikawa, Kiyotsugu
    Yanagihara, Kazuhiro
    Fukushima, Masanori
    Doi, Ryuichiro
    Chiba, Tsutomu
    PANCREAS, 2008, 36 (03) : 327 - 328
  • [30] GEMCITABINE AND S-1 COMBINATION THERAPY IN PATIENTS WITH ADVANCED STAGE OF PANCREATIC CANCER
    Ouchi, J.
    Hijioka, M.
    Harada, S.
    Maruyama, Y.
    Funakoshi, A.
    PANCREAS, 2008, 37 (04) : 488 - 488
12345